Diagnostic value ofJAK2V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

(2010) C. Nielsen et al.   HAEMATOLOGICA

Is the JAK2V617Fmutation detectable in healthy volunteers?

(2009) Christophe Martinaud et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders

(2009) Ana L. Basquiera et al.   Hematology

The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera

(2009) D Olcaydu et al.   LEUKEMIA

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

(2009) Outi Kilpivaara et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics

(2009) Ayalew Tefferi et al.   Nature Reviews Clinical Oncology

Association of Loss-of-Function Mutations in the ABCA1 Gene With High-Density Lipoprotein Cholesterol Levels and Risk of Ischemic Heart Disease

(2008) Ruth Frikke-Schmidt   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease

(2008) Jeppe Zacho et al.   NEW ENGLAND JOURNAL OF MEDICINE